Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Genentech completes investment in IDEC ahead of schedule

May 17, 1996

U.S. NDA filed for bropirimine

May 17, 1996

Promising clinical data for GVAX reported at scientific meeting

May 17, 1996

Human Genome Sciences claims chemokine beta-9 polypeptides and their antagonists

May 17, 1996

Melacine NDA filing in sight

May 10, 1996

Jenner Technologies in-licenses MTP-PE from Ciba

May 10, 1996

Allovectin-7 clinical results announced at AACR

May 3, 1996

Somatix receives patent coverage for GVAX

May 3, 1996

Preclinical results for DC101 presented at AACR

April 26, 1996

GVAX cleared to enter phase III testing

April 26, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Medline raises $6.3B in fourth med-tech IPO of December
BioWorld MedTech
Medline Inc. returned to the public markets with a blockbuster IPO of $6.26 billion, reportedly this year’s largest IPO globally. The upsized offering of more...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Acryl raises $28M IPO, aiming to bridge medical divide with AI
BioWorld MedTech
Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day,...